U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result

A potential escalation of U.S. import tariffs, particularly targeting pharmaceuticals manufactured overseas, poses a risk to the industry, especially companies reliant on foreign production. Amgen and Pfizer are vulnerable due to their manufacturing operations in Ireland, which has been specifically called out by the Trump administration, while AbbVie faces scrutiny despite downplaying tariff concerns, with analysts highlighting potential impacts on key drugs like Rinvoq and Humira; Bernstein analysts put AbbVie in their "highest risk category" of pharmaceutical companies that could feel the impact of newly imposed tariffs, suggesting they could cost the drugmaker hundreds of millions of dollars per year.

Analysis

The potential for renewed U.S. import tariffs, specifically a threatened 25% rate on foreign-made drugs and components, poses a significant risk to the pharmaceutical sector, particularly for companies with substantial overseas manufacturing. Amgen (AMGN) faces heightened vulnerability due to its generics business, which relies on low-cost overseas production, and its significant manufacturing presence in Ireland, a country targeted by the administration due to a $45.5 billion drug trade surplus with the U.S. in 2024 driven by tax incentives. Pfizer (PFE) is similarly exposed, with key drugs like Prevnar and Penbraya manufactured in Ireland, and components for Comirnaty and Eliquis (via a partnership with Bristol Myers Squibb) sourced from Germany and the Netherlands, respectively; these drugs represent approximately 10% of Pfizer's revenue. While Pfizer's CEO Albert Bourla indicated some existing U.S. capacity, shifting all production domestically could necessitate billions in new facility investments, a challenging prospect following its $43 billion Seagen acquisition. AbbVie (ABBV), despite CEO Rob Michael's statements downplaying tariff impacts and not including them in guidance, is considered by Bernstein analysts to be in the "highest risk category," potentially facing hundreds of millions in annual costs. This assessment likely stems from the international manufacturing of bestsellers like Rinvoq (Ireland, Canada, Germany) and Humira (Germany, Puerto Rico), even as AbbVie plans a $10 billion domestic manufacturing expansion over a decade amidst patent challenges and high marketing spend for Skyrizi. The overarching concern is that increased tariffs will compress already thin profit margins across the industry, as shifting production to the U.S. is both costly and time-intensive.

Key Decisions for Investors

• Investors should closely monitor developments regarding U.S. trade policy and potential pharmaceutical tariffs, particularly those targeting European manufacturing hubs like Ireland.
• Evaluate the geographic concentration of manufacturing for pharmaceutical holdings, giving particular scrutiny to companies like Amgen, Pfizer, and AbbVie, which have significant Irish or other European production links and face strongly negative sentiment.
• Consider the financial capacity of these companies to absorb increased input costs or fund multi-billion dollar shifts in their manufacturing footprint, especially in light of existing financial commitments or patent cliffs.
• Factor in potential margin erosion for pharmaceutical companies heavily reliant on imported drugs or active pharmaceutical ingredients if tariffs are implemented, and assess the credibility of management's mitigation strategies against independent analyst assessments.